HomeCompareAMTI vs JNJ

AMTI vs JNJ: Dividend Comparison 2026

AMTI yields 760.46% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMTI wins by $1810669.93M in total portfolio value
10 years
AMTI
AMTI
● Live price
760.46%
Share price
$0.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1810669.96M
Annual income
$1,438,546,236,154.04
Full AMTI calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AMTI vs JNJ

📍 AMTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMTIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMTI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMTI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMTI
Annual income on $10K today (after 15% tax)
$64,638.78/yr
After 10yr DRIP, annual income (after tax)
$1,222,764,300,730.93/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AMTI beats the other by $1,222,764,296,744.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMTI + JNJ for your $10,000?

AMTI: 50%JNJ: 50%
100% JNJ50/50100% AMTI
Portfolio after 10yr
$905334.99M
Annual income
$719,273,120,421.72/yr
Blended yield
79.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AMTI
Analyst Ratings
3
Hold
2
Sell
Consensus: Hold
Price Target
$1.70
+546.4% upside vs current
Range: $0.40 — $3.00
Altman Z
-39.2
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMTI buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMTIJNJ
Forward yield760.46%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1810669.96M$30.3K
Annual income after 10y$1,438,546,236,154.04$4,689.40
Total dividends collected$1780986.19M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$1.70$228.73

Year-by-year: AMTI vs JNJ ($10,000, DRIP)

YearAMTI PortfolioAMTI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$86,746$76,045.63$10,592$272.30+$76.2KAMTI
2$709,325$616,507.07$11,289$357.73+$698.0KAMTI
3$5,470,398$4,711,420.77$12,123$472.89+$5.46MAMTI
4$39,811,308$33,957,981.79$13,141$629.86+$39.80MAMTI
5$273,562,787$230,964,686.86$14,408$846.81+$273.55MAMTI
6$1,775,955,421$1,483,243,239.55$16,021$1,151.60+$1775.94MAMTI
7$10,899,466,861$8,999,194,560.48$18,122$1,588.22+$10899.45MAMTI
8$63,279,465,088$51,617,035,546.83$20,930$2,228.20+$63279.44MAMTI
9$347,779,178,316$280,070,150,671.65$24,792$3,191.91+$347779.15MAMTI
10$1,810,669,956,952$1,438,546,236,154.04$30,274$4,689.40+$1810669.93MAMTI

AMTI vs JNJ: Complete Analysis 2026

AMTIStock

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Full AMTI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AMTI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMTI vs SCHDAMTI vs JEPIAMTI vs OAMTI vs KOAMTI vs MAINAMTI vs ABBVAMTI vs MRKAMTI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.